A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

Inclusion Criteria: * Male or female subjects, 22 years or older * Visually significant cataract * Mild to moderate open angle glaucoma * On 1-5 IOP-lowering medications * Potential of good best corrected visual acuity post cataract extraction, in the investigator's judgment * Able and willing to comply with the protocol, including all follow-up visits. * Understand and sign the informed consent. Exclusion Criteria: * Any of the following prior treatments for glaucoma: * Laser trabeculoplasty ≤3 months prior to baseline * Implanted with iStent (All types), Cypass, Xen, Express, glaucoma draining device/valve, or Hydrus Device * Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, ECP or CPC * Acute angle closure, normal tension, traumatic, congenital, malignant, uveitic, neovascular or severe glaucoma as documented in subjects' medical record. * Concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to Investigator's office for follow-up visits). * Participation (≤ 30 days prior to baseline) in an interventional trial which could have a potential effect on the study outcome, as determined by the study investigator * Women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.